IDEXX Laboratories IDXX is balancing durable diagnostic growth, improving profitability and a broad innovation cycle against a valuation that remains well above major benchmarks. The operating picture is favorable, but the stock still requires investors to pay up for that quality.
The decision is whether current execution is enough to justify the premium without a better entry point.
IDXX Growth Stays Strong Despite Softer U.S. Visits
Worldwide Companion Animal Group Diagnostics recurring revenues increased 10.3% organically in the second quarter of 2026. Volume gains and roughly 4% average global net price improvement supported the increase.
That growth came even as U.S. same-store clinical visits declined an estimated 1.3% and wellness visits fell 3.4%. Higher diagnostic utilization and customer gains are helping offset softer veterinary traffic.
In the past year, IDXX shares have lost 13.1% compared with the industry’s 6.5% decline.Â
Â
Image Source: Zacks Investment Research
IDXX Innovation Expands Recurring Revenue
The inVue Dx installed base exceeded 9,000 instruments after 1,602 placements in the second quarter. IDEXX remains on pace for 5,500 placements in 2026, extending the base that can generate recurring consumable demand.
Cancer Dx has surpassed 10,000 ordering clinics globally and is being expanded to include mast cell tumor detection. More than 20% of global orders come from practices using a competing laboratory, broadening IDEXX's recurring revenue opportunity.
IDXX Margins Improve as Volume and Pricing Help
Gross margin expanded 140 basis points to 64% in the second quarter. Recurring revenue volume gains, operational productivity initiatives and net price realization supported the improvement.
Operating margin also increased 140 basis points to 35%, even as operating expenses rose 10% to $353.5 million. IDEXX is spending on commercial capabilities, innovation and information technology while still improving profitability.
IDXX Valuation Still Demands Strong Execution
IDXX trades at a forward 12-month price-to-earnings ratio of 34.69, versus 26.11 for its Zacks sub-industry, 21.1 for the Zacks Medical sector and 20.63 for the S&P 500. That premium leaves less room for execution setbacks.
Â
Image Source: Zacks Investment Research
DexCom, Inc. DXCM continues to build around glucose biosensing, including its Dexcom G7 and Stelo platforms. Its innovation focus gives investors another medical-technology growth profile to consider when weighing premium valuations.
Inogen, Inc. INGN focuses on respiratory products, including oxygen concentrators, airway-clearance devices and continuous positive airway pressure masks. Its different end market reinforces why IDXX's premium should be judged against the durability of its own recurring diagnostics model.
IDXX Faces Visit, Currency and Distribution Risks
Management assumes roughly a 1.5% decline in U.S. clinical visits during the second half of 2026. Reference laboratory testing remains more exposed to wellness activity, so prolonged weakness could limit recurring revenue growth.
Third-party distributor purchasing can create period-to-period variability that differs from underlying clinic consumption. Foreign exchange adds another risk, with updated currency assumptions reducing the full-year revenue outlook by $15 million.
IDXX Signals Favor Growth Over Value
The operating case remains attractive, but the valuation argues for discipline. IDXX looks better suited to a hold-or-wait stance than an aggressive new entry while investors assess whether growth and margin gains can keep supporting the premium.
The stock currently carries a Zacks Rank #3 (Hold), along with a VGM Score of B, Growth Score of A, Momentum Score of B and Value Score of D. The favorable Growth and Momentum Scores support the operating-strength case, while the Value Score reinforces the valuation concern.
A Zacks Rank #3 can be appropriate for holding, while the Style Scores complement the Rank rather than replace it. For prospective buyers, the mix supports patience rather than treating growth alone as sufficient reason to ignore price.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Â
Â
Â
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.